141 related articles for article (PubMed ID: 11022970)
1. Inhibition of cytokine release by and cardiac effects of type IV phosphodiesterase inhibition in early, profound endotoxaemia in vivo.
Tofovic SP; Zacharia LC; Carcillo JA; Jackson EK
Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):787-92. PubMed ID: 11022970
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of adenosine deaminase attenuates endotoxin-induced release of cytokines in vivo in rats.
Tofovic SP; Zacharia L; Carcillo JA; Jackson EK
Shock; 2001 Sep; 16(3):196-202. PubMed ID: 11531021
[TBL] [Abstract][Full Text] [Related]
3. Type IV phosphodiesterase inhibition improves cardiac contractility in endotoxemic rats.
Thomas NJ; Carcillo JA; Herzer WA; Mi Z; Tofovic SP; Jackson EK
Eur J Pharmacol; 2003 Mar; 465(1-2):133-9. PubMed ID: 12650842
[TBL] [Abstract][Full Text] [Related]
4. Chronic type IV phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine.
Thomas NJ; Carcillo JA; Herzer WA; Mi Z; Jackson EK
J Pharmacol Exp Ther; 2001 Jan; 296(1):168-74. PubMed ID: 11123377
[TBL] [Abstract][Full Text] [Related]
5. Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines.
Herzer WA; Thomas NJ; Carcillo JA; Tofovic SP; Jackson EK
J Cardiovasc Pharmacol; 1998 Nov; 32(5):769-76. PubMed ID: 9821851
[TBL] [Abstract][Full Text] [Related]
6. Lipopolysaccharide-induced acute renal failure in conscious rats: effects of specific phosphodiesterase type 3 and 4 inhibition.
Jonassen TE; Graebe M; Promeneur D; Nielsen S; Christensen S; Olsen NV
J Pharmacol Exp Ther; 2002 Oct; 303(1):364-74. PubMed ID: 12235272
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats.
Kyoi T; Kitazawa S; Tajima K; Zhang X; Ukai Y
J Pharmacol Sci; 2004 Jul; 95(3):321-8. PubMed ID: 15272207
[TBL] [Abstract][Full Text] [Related]
8. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
9. Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine.
Carcillo JA; Herzer WA; Mi Z; Thomas NJ; Jackson EK
J Pharmacol Exp Ther; 1996 Dec; 279(3):1197-204. PubMed ID: 8968341
[TBL] [Abstract][Full Text] [Related]
10. Pentoxifylline improves circulatory failure and survival in murine models of endotoxaemia.
Wu CC; Liao MH; Chen SJ; Yen MH
Eur J Pharmacol; 1999 May; 373(1):41-9. PubMed ID: 10408250
[TBL] [Abstract][Full Text] [Related]
11. The influence of phosphodiesterase inhibitor, rolipram, on hemodynamics in lipopolysaccharide-treated rats.
Dutta P; Ryan DE; Tabrizchi R
Jpn J Pharmacol; 2001 Mar; 85(3):241-9. PubMed ID: 11325016
[TBL] [Abstract][Full Text] [Related]
12. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
Muise ES; Chute IC; Claveau D; Masson P; Boulet L; Tkalec L; Pon DJ; Girard Y; Frenette R; Mancini JA
Biochem Pharmacol; 2002 Apr; 63(8):1527-35. PubMed ID: 11996895
[TBL] [Abstract][Full Text] [Related]
13. Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells.
Yoshimura T; Kurita C; Nagao T; Usami E; Nakao T; Watanabe S; Kobayashi J; Yamazaki F; Tanaka H; Nagai H
Gen Pharmacol; 1997 Oct; 29(4):633-8. PubMed ID: 9352314
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties.
Reimund JM; Raboisson P; Pinna G; Lugnier C; Bourguignon JJ; Muller CD
Biochem Biophys Res Commun; 2001 Oct; 288(2):427-34. PubMed ID: 11606060
[TBL] [Abstract][Full Text] [Related]
15. The effect of oxidative stress on macrophages and lung epithelial cells: the role of phosphodiesterases 1 and 4.
Brown DM; Hutchison L; Donaldson K; MacKenzie SJ; Dick CA; Stone V
Toxicol Lett; 2007 Jan; 168(1):1-6. PubMed ID: 17129690
[TBL] [Abstract][Full Text] [Related]
16. Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats.
Chi ZL; Hayasaka S; Zhang XY; Hayasaka Y; Cui HS
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2497-502. PubMed ID: 15277469
[TBL] [Abstract][Full Text] [Related]
17. Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure.
Adachi H; Tanaka H
J Cardiovasc Pharmacol; 1997 Jun; 29(6):763-71. PubMed ID: 9234657
[TBL] [Abstract][Full Text] [Related]
18. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.
Souza DG; Cassali GD; Poole S; Teixeira MM
Br J Pharmacol; 2001 Nov; 134(5):985-94. PubMed ID: 11682446
[TBL] [Abstract][Full Text] [Related]
19. Specific type IV phosphodiesterase inhibitor ameliorates cerulein-induced pancreatitis in rats.
Sato T; Otaka M; Odashima M; Kato S; Jin M; Konishi N; Matsuhashi T; Watanabe S
Biochem Biophys Res Commun; 2006 Jul; 346(1):339-44. PubMed ID: 16759642
[TBL] [Abstract][Full Text] [Related]
20. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
